Hypocellular myelodysplastic syndromes (MDS): new proposals

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Bone marrow (BM) cellularity is a key parameter in MDS classification and prognosis.
• The definition and impact of hypocellular MDS remain debated.

Purpose of the Study:

• To investigate whether hypocellular MDS differs from normo/hypercellular MDS.
• To compare different methods of identifying hypocellular MDS cases.
• To evaluate the prognostic significance of BM cellularity in MDS.

Main Methods:

• Identified hypocellular MDS cases using age-corrected BM cellularity (28 patients) and an arbitrary BM cellularity threshold (25 patients).
• Compared these hypocellular groups with normo/hypercellular MDS cases (72 patients).
• Analyzed patient demographics, peripheral blood and BM parameters, FAB subtypes, karyotypes, leukemic transformation, and survival.

Main Results:

• Hypocellular MDS cases, identified by either method, showed similar features in age, sex, blood/marrow parameters, FAB subtypes, karyotypes, leukemic transformation, and survival compared to normo/hypercellular MDS.
• Age-corrected grouping revealed discrepancies in patient selection compared to an arbitrary cellularity threshold.
• BM cellularity did not appear to be a significant prognostic factor in MDS.

Conclusions:

• Age-correction of BM cellularity is recommended for creating comparable patient series for analysis.
• Hypocellular MDS shares similar prognostic outcomes with normo/hypercellular MDS.
• BM cellularity itself may not be a critical determinant of prognosis in MDS.